Search
Paclitaxel Treatment Options
A collection of 2015 research studies where Paclitaxel is the interventional treatment. These studies are located in the United States. Paclitaxel is used for conditions such as Breast Cancer, Ovarian Cancer and Non-Small Cell Lung Cancer.
673 - 684 of 2015
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Studying an Investigational Virus Vaccine
Recruiting
The main objectives of this study are to assess the safety and effectiveness of an investigational vaccine aimed at preventing norovirus, commonly known as the stomach flu. Participants will be randomly assigned to receive either the investigational vaccine or a placebo. Should you express interest, you will be contacted directly by the research site, which will provide further details and answer any questions you may have about study requirements, risks/benefits, and any compensation.
Conditions:
Healthy
Interested in vaccine studies
All Conditions
Preventative Trials
Featured Trial
Type 2 Diabetes Clinical Trial
Recruiting
Can changing your breakfast improve your type 2 diabetes? If you have an HbA1C of 7.0% or higher, you are invited to participate in an online study at the University of Michigan.
Conditions:
Type 2 Diabetes
Diabetes Mellitus Type 2 in Obese
Diabetes Type Two
Type 2 Diabetes Mellitus
Diabete Type 2
Featured Trial
Evaluating an Investigational Treatment for Hidradenitis Suppurativa
Recruiting
The main objectives of this Phase 2 study are to evaluate the safety and effectiveness of an investigational medication in adults with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition. Participants will be randomly assigned to receive the investigational treatment or a placebo. Should you express interest, the research site will contact you directly to provide further details and address any questions you may have about study requirements, risks/benefits, and compensation.
Conditions:
All Conditions
Hidradenitis suppurativa (Skin disorder)
Dermatology
Study of Lonsurf in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Advanced (PDAC)
Terminated
The purpose of this study is to determine the recommended phase 2 dose (RP2D) of the combination of lonsurf, gemcitabine and nab-paclitaxel in Pancreatic ductal adenocarcinoma (PDAC)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/02/2024
Locations: Indiana University Melvin & Bren Simon Cancer Center, Indianapolis, Indiana
Conditions: Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma
Preoperative Nab-paclitaxel, Cisplatin, and Gemcitabine Chemotherapy With or Without Infigratinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, The OPTIC Trial
Withdrawn
This phase II trial assesses the feasibility (including both safety and tolerability) of conducting Next Generation Sequencing and administering targeted therapy (infigratinib) in the preoperative setting for patients with intrahepatic cholangiocarcinoma that can be removed by surgery (resectable). Chemotherapy drugs, such as nab-paclitaxel, cisplatin, and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by sto... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/20/2023
Locations: Emory University Hospital Midtown, Atlanta, Georgia +2 locations
Conditions: Resectable Intrahepatic Cholangiocarcinoma, Stage 0 Intrahepatic Cholangiocarcinoma AJCC v8, Stage I Intrahepatic Cholangiocarcinoma AJCC v8, Stage II Intrahepatic Cholangiocarcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8
Adjuvant Sequential & Concurrent CarboTaxol + Radiotherapy for High Risk Endometrial Cancer
Active Not Recruiting
The purpose of this trial is to evaluate the safety of sequential and concurrent carboplatin and paclitaxel with adjuvant external beam radiotherapy for locally advanced endometrial cancer. The primary objective is to assess the acute toxicities namely grade 3-4 non hematologic and grade 4 hematologic toxicities associated with the above regimen. The null hypothesis is that the unacceptable toxic response rate is ≥40%. This will be tested against a one-sided alternative that the toxicity rate is... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/15/2023
Locations: Loyola University Medical Center, Marywood, Illinois
Conditions: Endometrial Cancer
Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery
Active Not Recruiting
Study to compare the safety and efficacy of oregovomab versus placebo, administered in combination with specific cycles of a standard six-cycle chemotherapy regimen (paclitaxel and carboplatin), for the treatment of subjects with newly diagnosed advanced ovarian cancer who have undergone optimal debulking.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/15/2023
Locations: Honor Health, Phoenix, Arizona +147 locations
Conditions: Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer, Ovarian Serous Adenocarcinoma, Fallopian Tube Neoplasms, Fallopian Tube Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Peritoneal Cancer, Peritoneal Carcinoma, Peritoneal Neoplasms
Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD)
Completed
The purpose of this study is to determine if the combination of paclitaxel protein bound, gemcitabine, cisplatin, paricalcitol are effective in individuals with previously untreated metastatic pancreatic cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/13/2023
Locations: HonorHealth Research Institute, Scottsdale, Arizona
Conditions: Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Pancreatic Adenocarcinoma, Pancreas Metastases, Adenocarcinoma
A Study of ABT-165 in Subjects With Solid Tumors
Completed
This is a Phase 1/1b open-label study evaluating the safety, pharmacokinetics (PK), and preliminary efficacy of ABT-165 when administered as monotherapy and in combination with paclitaxel or 5-fluoruracil, folinic acid and irinotecan (FOLFIRI) or ABBV-181 with/without paclitaxel in subjects with advanced solid tumors. Enrollment to Cohorts A, B were completed and for Cohorts C and D are recruiting.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
12/13/2023
Locations: HonorHealth Research Institute - Pima /ID# 105677, Scottsdale, Arizona +9 locations
Conditions: Advanced Solid Tumors
Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer
Active Not Recruiting
This phase I trial studies the side effects, best dose, and best way to give pembrolizumab when given together with paclitaxel, carboplatin, and radiation therapy in treating patients with stage II-IIIB non-small cell lung cancer. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by sto... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/12/2023
Locations: Yale Cancer Center, New Haven, Connecticut +2 locations
Conditions: Stage II Non-Small Cell Lung Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer
Study of ORIC-101 in Combination With Anticancer Therapy
Terminated
The purpose of this study is to establish the recommended Phase 2 dose (RP2D), safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of ORIC-101 in combination with nab-paclitaxel or other anticancer therapies when administered to patients with advanced or metastatic solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/11/2023
Locations: Stanford Cancer Institute, Palo Alto, California +11 locations
Conditions: Solid Tumor
Chemotherapy & Bevacizumab for Human Epidermal Growth Factor Receptor 2 (HER2)/Neu-Negative Stage II/III Breast Cancer
Terminated
RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride, cyclophosphamide, paclitaxel, and gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab ma... Read More
Gender:
FEMALE
Ages:
19 years and above
Trial Updated:
12/07/2023
Locations: University of Nebraska Medical Center, Omaha, Nebraska
Conditions: HER2-negative Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma
Terminated
The purpose of this trial is to determine the benefit of the combination of nab-paclitaxel plus gemcitabine given for 6 cycles, followed by maintenance nab-paclitaxel alone, in patients with cisplatin-ineligible or cisplatin-incurable advanced urothelial carcinoma (UC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/01/2023
Locations: Florida Cancer Specialists - South, Fort Myers, Florida +4 locations
Conditions: Urothelial Carcinoma, Bladder Cancer, Transitional Cell Carcinoma
Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC)
Completed
Study of efficacy of nivolumab with neoadjuvant chemotherapy in patients with IBC
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/28/2023
Locations: Indiana University, Bloomington, Indiana +1 locations
Conditions: Breast Cancer
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Terminated
The purpose of this trial is to explore the activity and safety of everolimus +/- paclitaxel as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/21/2023
Locations: University of Alabama Hematology Oncology Clinic at Medical West, Birmingham, Alabama +10 locations
Conditions: Transitional Cell Carcinoma, Bladder Carcinoma, Urothelial Carcinoma
673 - 684 of 2015